Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
India reserved 75% of its FY2026-27 defence capital-acquisition budget, or Rs 1,39,000 crore, for domestic procurement while cumulative defence FDI reached USD 26.5 million.
CEAQ Singapore faces a pending Singapore High Court claim seeking 51,000 Tonbo shares, compensation or winding-up over alleged unextended subscription rights.
Tonbo’s working-capital days reached 517 in Fiscal 2026 from 152 in Fiscal 2024, as Rs 219.485 crore of inventory and long production cycles absorbed cash.
Tonbo acquired a ₹183.191 crore intellectual-property portfolio from CEAQ Singapore through five March 11, 2024 assignment agreements covering infrared imaging, algorithms and stabilisation.
Tonbo’s 17.43% promoter stake falls short of the 20% post-offer contribution threshold, requiring non-promoter CEAQ Singapore, which holds 25.47%, to provide locked-in shares.
Tonbo’s European revenue share fell from 65.34% in Fiscal 2025 to 0.13% in Fiscal 2026 after execution of a Rs 452.7 crore order.
Tonbo Imaging India Ltd. IPO opens 15 Oct 2026 and closes 19 Oct 2026. The RHP context indicates an OFS of up to 1.22 crore shares; price band awaited.
Sahajanand Medical Technologies’ FY26 profit after tax reached Rs 69.082 crore as revenue rose 18.1%, while Rs 130.030 crore of net investing outflow exceeded operating cash flow.
Sahajanand Medical permits 100% automatic-route foreign investment in medical-device manufacturing, but government approval applies above 10% border-country beneficial ownership or control.
SMT’s structural-heart devices accounted for 16.77% of Fiscal 2026 revenue, up from 12.26% in Fiscal 2024 as TAVI and occluder sales expanded.
SMT overseas sales accounted for 73.87% of Fiscal 2026 revenue from operations as Europe supplied 38.66%, exceeding India’s 26.13% share.
India’s 2017 cardiac-stent price caps cut prices by up to 85%, while drug-eluting stent sales volumes are forecast to grow 11% annually through 2030.
SMT’s 36.71% promoter stake includes Shree Hari Trust, where two promoters hold approval or consultation roles over specified trust decisions.
Sahajanand Medical Technologies Limited reported no FY26 output from Hyderabad transcatheter aortic valve implantation and occluder lines, while Surat’s drug-coated balloon line used 1.81% of capacity.
Sahajanand Medical Technologies Limited reported Rs 320.633 crore of consolidated borrowings at June 30, 2026, with 79.34% current under loan agreements.
Sahajanand Medical Technologies disclosed $300,000 in annual contracts with director-led firms, while its chairman emeritus is entitled to Rs 20.4 lakh of monthly office rent.
